Enlivex Therapeutics Ltd
ENLV
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.15M
Close$
$0.42
51.1% downside
Current Fair Value
51.1% downsideOvervalued by 51.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.15 Million |
|---|---|
| Enterprise Value | $14.78 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $405.6 |
| Beta | 1.42 |
| Outstanding Shares | 3,029,684 |
Return
| Return on Equity | 63.85% |
|---|---|
| Return on Assets | 53.10% |
| Return on Invested Capital | -0.63% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.01 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 11, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 18, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4661▲ 46.61% |
|---|---|
| Total Calls | 88,400▲ 266.80% |
| Total Puts | 41,200▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.35%▲ 1.38% |
|---|---|
| Total Invested | $2.34M▼ 30.81% |
| Investors Holding | 27▼ 9.00% |
ESG Score
No data
About Enlivex Therapeutics Ltd
CEO: Dror Mevorach